ARTERY THERAPEUTICS INC
San Ramon, CA · Biotech · Private
CS6253, a selective ABCA1 transporter agonist peptide for treating APOE4-driven Alzheimer's disease and dementias
arterytx.com →- Grants
- $13M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease | $479,682 | |
| Federal grant | Department of Health and Human Services · Phase II · CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease | $2,375,985 | |
| Federal grant | Department of Health and Human Services · Phase II · CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease | $2,375,985 | |
| Federal grant | Department of Health and Human Services · Phase II · A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253 | $499,197 | |
| Federal grant | Department of Health and Human Services · Phase II · A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253 | $2,482,205 | |
| Federal grant | Department of Health and Human Services · Phase II · A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253 | $2,482,205 | |
| Federal grant | Department of Health and Human Services · Phase II · Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in Wistar rats and Cynomolgus monkeys | $2,454,521 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2897 | Graywolf Therapeutics | — | — |
| 2898 | Beeline Medicines | — | — |
| 2899 | GENERATION BIOTECH, LLC | — | — |
| 2900 | ARTERY THERAPEUTICS INC | — | — |
| 2901 | FIMBRION THERAPEUTICS INC | — | — |
| 2902 | 712 North Inc. | — | — |
| 2903 | SIMMBION LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods Of Treating Peripheral Nervous System Myelination Conditionsapplication
- Methods of Treating Peripheral Nervous System Myelination Conditionsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.